

Supplemental Table S3. The relationship between percent reduction of psoriasis area and severity index (PASI) at week 12 versus presence or absence of nail lesions, diabetes mellitus, current smoking, or bio-switch

Biologics (<i>n</i>)		Nail lesions			Diabetes mellitus			Current smoking			Bio-switch		
		Absence	Presence	<i>p</i>	Absence	Presence	<i>p</i>	Absence	Presence	<i>p</i>	Absence	Presence	<i>p</i>
Whole	<i>n</i> (%)	23 (41.8)	30 (54.6)		47 (85.5)	8 (14.6)		14 (25.5)	37 (67.3)		39 (70.9)	16 (29.1)	
TNF- α inhibitors (55) †	Percent reduction of PASI	75 [53-86]	67 [39-83]	0.435	74 [42-83]	71 [40-91]	0.867	71.0 [45-81]	74 [50-88]	0.712	76 [49-90]	56 [33-80]	0.201
IFX (28) †	<i>n</i> (%)	11 (39.3)	15 (53.6)		25 (89.3)	3 (10.7)		8 (28.6)	17 (60.7)		27 (96.4)	1 (3.6)	
	Percent reduction of PASI	77 [61-82]	77 [41-92]	0.755	77 [44-91]	88 [44-94]	0.629	78 [47-82]	77 [63-92]	0.705	77 [41-91]	75 [75-75]	0.804
ADA (15) ‡	<i>n</i> (%)	5 (33.3)	10 (66.7)		11 (73.3)	4 (26.7)		2 (13.3)	12 (80.0)		5 (33.3)	10 (66.7)	
	Percent reduction of PASI	67 [56-100]	56 [34-76]	0.269	73 [29-87]	93 [47-97]	0.383	44.44 [38.89- 50.00]	62.00 [38.04- 80.02]	0.522	67 [54-100]	56 [35-76]	0.462
CZP (12) ‡	<i>n</i> (%)	7(58.3)	5(41.7)		11(91.7)	1(8.3)		4(33.3)	8(66.7)		7(58.3)	5(41.7)	

	Percent reduction of PASI	65.2 ± 26.6	57.6 ± 28.8	0.646	57.2 ± 36.0	66.9 ± 14.0	0.55	62.82 ± 30.0	61.64 ± 26.81	0.946	68.79 ± 13.41	52.59 ± 38.38	0.319
--	---------------------------------	----------------	----------------	-------	----------------	----------------	------	-----------------	------------------	-------	------------------	------------------	-------

TNF- α , tumor necrosis factor- α ; IFX, infliximab; ADA, adalimumab; CZP, certolizumab pegol

†Data are provided as the median [interquartile range], analyzed by Mann-Whitney U test.

‡Data are provided as mean \pm standard deviation, analyzed by Student's *t*-test.